Patents Assigned to Zhongshan Hospital of Fudan University
-
Patent number: 11779575Abstract: The use of a Wnt inhibitor Wnt-C59 in the preparation of a drug for treating SCN5A mutation-induced dilated cardiomyopathy (DCM) is provided. With SCN5A genotype detection as a breakthrough point, a Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt?-Catenin pathway caused by SCN5A gene mutation, thereby improving the prognosis of cardiac function in a patient with SCN5A gene mutation-induced DCM. In experiments, aging and adriamycin-induced DCM models are constructed, and the therapeutic effect of Wnt-C59 on DCM is detected through indexes such as changes in cardiac function and activation of related signal molecules, which provides a theoretical basis for use of Wnt-C59 in the clinical treatment of DCM. A new treatment method for SCN5A mutation-induced DCM is provided to bring dawn to such patients and has promising application prospects.Type: GrantFiled: August 6, 2021Date of Patent: October 10, 2023Assignee: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Junbo Ge, Aijun Sun, Jingjing Hu, Kun Yang
-
Publication number: 20220370428Abstract: The use of a Wnt inhibitor Wnt-C59 in the preparation of a drug for treating SCN5A mutation-induced dilated cardiomyopathy (DCM) is provided. With SCN5A genotype detection as a breakthrough point, a Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt?-Catenin pathway caused by SCN5A gene mutation, thereby improving the prognosis of cardiac function in a patient with SCN5A gene mutation-induced DCM. In experiments, aging and adriamycin-induced DCM models are constructed, and the therapeutic effect of Wnt-C59 on DCM is detected through indexes such as changes in cardiac function and activation of related signal molecules, which provides a theoretical basis for use of Wnt-C59 in the clinical treatment of DCM. A new treatment method for SCN5A mutation-induced DCM is provided to bring dawn to such patients and has promising application prospects.Type: ApplicationFiled: August 6, 2021Publication date: November 24, 2022Applicant: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Junbo GE, Aijun SUN, Jingjing HU, Kun YANG
-
Patent number: 11479592Abstract: An erythropoiet-derived peptide having an amino acid sequence as shown in SEQ ID NO: 1. A, method for preparing the above-described erythropoietin-derived peptide. Also provided is the rrse of the above-described erythropoietin-derived peptide fo the preparation of medicament for reatin$ nerve cell damage. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating hypoxic brain damage. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating epilepsy. The novel EPO-derived peptide of the present invention has a small molecular weight and can penetrate the blood-brain barrier. Moreover, it is a small-molecule polypeptide derived from a functional protein in the human body, having an extremely small side effect to the human body compared with other developed and synthesized thugs, thereby it has a good clinical application prospect.Type: GrantFiled: March 7, 2018Date of Patent: October 25, 2022Assignee: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Xin Wang, Jing Ding, Tingting Wu
-
Patent number: 11331084Abstract: A portable liquid collection device includes a liquid collector, a guide tube and a liquid collection tube. The liquid collector includes a flowing liquid hole and an anti-slip structure. The guide tube includes two ends, one end connects to the liquid collector, and the other end is in a needle-shaped structure and connects to the liquid collection tube. A gas channel and a liquid channel are disposed in a tube body of the guide tube. The guide tube is provided with an outer annular structure. The liquid collection tube includes a collection tube body and a collection tube cover. The collection tube cover includes a tube cover body and a blocking plug. A placing slot for placing the blocking plug is disposed between the top and the bottom of the tube cover body.Type: GrantFiled: May 8, 2020Date of Patent: May 17, 2022Assignee: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Lei Sheng, Xuening Li, Changpeng Wang
-
Publication number: 20210353265Abstract: A portable liquid collection device includes a liquid collector, a guide tube and a liquid collection tube. The liquid collector includes a flowing liquid hole and an anti-slip structure. The guide tube includes two ends, one end connects to the liquid collector, and the other end is in a needle-shaped structure and connects to the liquid collection tube. A gas channel and a liquid channel are disposed in a tube body of the guide tube. The guide tube is provided with an outer annular structure. The liquid collection tube includes a collection tube body and a collection tube cover. The collection tube cover includes a tube cover body and a blocking plug. A placing slot for placing the blocking plug is disposed between the top and the bottom of the tube cover body.Type: ApplicationFiled: May 8, 2020Publication date: November 18, 2021Applicant: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Lei SHENG, Xuening LI, Changpeng WANG
-
Publication number: 20210171595Abstract: An erythropoietin-derived peptide having an amino acid sequence as shown in SEQ ID NO: 1. A method for preparing the above-described erythropoietin-derived peptide. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating nerve cell damage. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating hypoxic brain damage. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating epilepsy. The novel EPO-derived peptide of the present invention has a small molecular weight and can penetrate the blood-brain barrier. Moreover, it is a small-molecule polypeptide derived from a functional protein in the human body, having an extremely small side effect to the human body compared with other developed and synthesized drugs, thereby it has a good clinical application prospect.Type: ApplicationFiled: March 7, 2018Publication date: June 10, 2021Applicant: Zhongshan Hospital, Fudan UniversityInventors: Xin WANG, Jing DING, Tingting WU
-
Patent number: 10610561Abstract: The present invention provides a pharmaceutical composition or a cosmetic product which can accelerate production of ceramide in cells. The ceramide production-accelerating agent contains a plant selected from the group consisting of Radix Heraclei Scabridi, Rhizoma Dioscoreae, Radix Rehmanniae, Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Radix Et Rhizoma Rhei, Pseudobulbus Bletillae, Radix Polygoni Multiflori, Radix Platycodi, and Herba Leonuri, or an extract thereof as an active ingredient. Further, the present invention provides a moisturizing agent containing a plant selected from the group consisting of Herba Leonuri and Rhizoma Dioscoreae, or an extract thereof as an active ingredient.Type: GrantFiled: January 20, 2015Date of Patent: April 7, 2020Assignees: Zhongshan Hospital of Fudan University, Kao CorporationInventors: Wan Zhang Qin, Chun Xin Yang, Fan Qi Kong, Hiroshi Nojiri, Shotaro Ito
-
Patent number: 10603168Abstract: A valve clamp for treating the cardiac valve regurgitation. The valve clamp includes a first clamp part, a second clamp part, and a connecting part. The first clamp part has the first clamping arms. The second clamp part has a corresponding number of second clamping arms. The first clamping arm and the second clamping arm can clip an object therebetween through the interaction force generated by closing and pushing against each other. Moreover, the valve clamp can also include a closed ring, which is sleeved outside the periphery of the first clamp part and the periphery of the second clamp part, such that the clamping arms can close as needed, and the clamping is tighter. The valve clamp has the advantages of a minimally invasive implantation, a simple manufacture, a low difficulty of operation, good effects, etc.Type: GrantFiled: February 15, 2017Date of Patent: March 31, 2020Assignee: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Wenzhi Pan, Daxin Zhou, Junbo Ge, Leilei Cheng
-
Publication number: 20190000623Abstract: A valve clamp for treating the cardiac valve regurgitation. The valve clamp includes a first clamp part, a second clamp part, and a connecting part. The first clamp part has the first clamping arms. The second clamp part has a corresponding number of second clamping arms. The first clamping arm and the second clamping arm can clip an object therebetween through the interaction force generated by closing and pushing against each other. Moreover, the valve clamp can also include a closed ring, which is sleeved outside the periphery of the first clamp part and the periphery of the second clamp part, such that the clamping arms can close as needed, and the clamping is tighter. The valve clamp has the advantages of a minimally invasive implantation, a simple manufacture, a low difficulty of operation, good effects, etc.Type: ApplicationFiled: February 15, 2017Publication date: January 3, 2019Applicant: Zhongshan Hospital, Fudan UniversityInventors: Wenzhi Pan, Daxin ZHOU, Junbo GE, Leilei CHENG
-
Publication number: 20150132415Abstract: The present invention provides a pharmaceutical composition or a cosmetic product which can accelerate production of ceramide in cells. The ceramide production-accelerating agent contains a plant selected from the group consisting of Radix Heraclei Scabridi, Rhizoma Dioscoreae, Radix Rehmanniae, Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Radix Et Rhizoma Rhei, Pseudobulbus Bletillae, Radix Polygoni Multiflori, Radix Platycodi, and Herba Leonuli, or an extract thereof as an active ingredient. Further, the present invention provides a moisturizing agent containing a plant selected from the group consisting of Herba Leonuri and Rhizoma Dioscoreae, or an extract thereof as an active ingredient.Type: ApplicationFiled: January 20, 2015Publication date: May 14, 2015Applicants: Zhongshan Hospital of Fudan University, Kao CorporationInventors: Wan Zhang QIN, Chun Xin Yang, Fan Qi Kong, Hiroshi Nojiri, Shotaro Ito
-
Patent number: 8889188Abstract: This invention involves two fields of photoelectron information materials and pharmaceuticals, especially refers to the self-assembly of conducting photoluminescence nanomedicine crystals and thin films and their preparation processes. In the invention, self-assembling unitary, binary, ternary and quaternary complexes of an antioxidase antioxidant, an agonist of the ?-adrenergic receptors, an agonist of the P2-purinergic receptors and an antagonist of benzalkonium-typed calcium channels is to employ an interaction of inelastic electron tunneling, which possesses photoelectron properties of inelastic electron tunneling and photoluminescence with the central wavelength ˜500 nm and the wavelength wide ˜200 nm in the size-controlled square or cubic geometrical complexes. The invention is not only beneficial for drug discovery targeted disease mechanisms, but also profitable for inventions of photoelectron sensing new materials.Type: GrantFiled: December 29, 2005Date of Patent: November 18, 2014Assignee: Zhongshan Hospital, Fudan UniversityInventor: Yan Fang
-
Patent number: 8574570Abstract: A bi-stable quantum wire array of self-assembled nano-medicine and its process present in the invention. The bi-stable quantum wire array with quantum bit and kondo effect is prepared by self-assembling an oxygen radical antagonist of antioxidase, a ?-receptor agonist, a P2 receptor agonist, a calcium antagonist of phenyl alkyl amines, and/or a nucleotide monomer of purines and its binary, ternary, quaternary or quinary compounds and using the interaction of inelastic electron tunneling. The invention not only benefits mechanisms-targeted multifunctional device discoveries, but also profits inventions of nanometer structures, novel materials, quantum calculation devices, biosensors and quantum bit magnetic random access memories (MRAM).Type: GrantFiled: January 15, 2008Date of Patent: November 5, 2013Assignee: Zhongshan Hospital, Fudan UniversityInventors: Yan Fang, Rong Wu
-
Patent number: 8304758Abstract: Preparation of oxidation-reduction (redox) nano-medicine quantum dot room temperature superconductor quantum bit (qubit) networks includes processes of making unitary, binary, ternary, an d/or quaternary liquid pharmaceutical ingredients of an antioxidase antioxidant, a ?-adrenergic receptor agonist, a P2-purinergic receptor agonist, and/or a phenylalkylamine calcium channel blocker in combination with either 1:20 xanthine oxidase (XO):xanthine (X) or X alone in a liquid phase by using the L16(2)15 and L9(3)4 orthogonal optimization design protocols and modulating spatial distance constraint from about 0.1 ? to about 200 ? as well as a 10 class clean bottom-up self-assembly approach.Type: GrantFiled: December 19, 2007Date of Patent: November 6, 2012Assignee: Zhongshan Hospital, Fudan UniversityInventor: Yan Fang
-
Patent number: 8252538Abstract: Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.Type: GrantFiled: November 1, 2007Date of Patent: August 28, 2012Assignees: The Ohio State University, The United States of America as represented by the Secretary of the Department of Health and Human Services National Institute of Health, Office of Technology Transfer, Liver Cancer Institute and Zhongshan Hospital, Fudan UniversityInventors: Carlo M. Croce, Xin W. Wang, Anuradha Budhu, Zhao-you Tang
-
Publication number: 20120149581Abstract: Preparation of oxidation-reduction (redox) nano-medicine quantum dot room temperature superconductor quantum bit (qubit) networks includes processes of making unitary, binary, ternary, and/or quaternary liquid pharmaceutical ingredients of an antioxidase antioxidant, a ?-adrenergic receptor agonist, a P2-purinergic receptor agonist, and/or a phenylalkylamine calcium channel blocker in combination with either 1:20 xanthine oxidase (XO):xanthine (X) or X alone in a liquid phase by using the L16(2)15 and L9(3)4 orthogonal optimization design protocols and modulating spatial distance constraint from about 0.1 ? to about 200 ? as well as a 10 class clean bottom-up self-assembly approach.Type: ApplicationFiled: December 19, 2007Publication date: June 14, 2012Applicant: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventor: Yan Fang
-
Publication number: 20110200694Abstract: The present invention provides a pharmaceutical composition or a cosmetic product which can accelerate production of ceramide in cells. The ceramide production-accelerating agent contains a plant selected from the group consisting of Radix Heraclei Scabridi, Rhizoma Dioscoreae, Radix Rehmanniae, Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Radix Et Rhizoma Rhei, Pseudobulbus Bletillae, Radix Polygoni Multiflori, Radix Platycodi, and Herba Leonuli, or an extract thereof as an active ingredient. Further, the present invention provides a moisturizing agent containing a plant selected from the group consisting of Herba Leonuri and Rhizoma Dioscoreae, or an extract thereof as an active ingredient.Type: ApplicationFiled: August 17, 2009Publication date: August 18, 2011Applicants: Zhongshan Hospital of Fudan University, Kao CorporationInventors: Wan Zhang Qin, Chun Xin Yang, Fan Qi Kong, Hiroshi Nojiri, Shotaro Ito
-
Self-Directing And Self-Assembling Nanomedicine Into Quantized Conductance Junctions And Its Process
Publication number: 20080193434Abstract: A self-directed and self-assembled nanomedicine of quantized conductive junction and its preparation process are introduced. In the present disclosure, bio-organic medicine proteins are prepared into a quantized conductive junction with a nanostructure quantum dot and a polymer monolayer on an inorganic silicon surface by seven cooperative modes; and the preparation process of this inorganic-organic-biological hetero-polymer nano-structure component with free radical electrons, aromatic hetercycle structures, bio-fluorescence, and redox bioactivity is consist of making unitary, binary, ternary, and/or quaternary liquid biochemical medicines ingredients of an antioxidase antioxidant, a ?-adrenergic receptor agonist, a P2-purinergic receptor agonist, and/or a phenylalkylamine calcium channel blocker into a solid state quantized conductance junctions using L 6(2)15 and L9(3)4 orthogonal protocol.Type: ApplicationFiled: January 23, 2006Publication date: August 14, 2008Applicant: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventor: Yan Fang -
Publication number: 20080166333Abstract: ABSTRACT A bi-stable quantum wire array of self-assembled nano-medicine and its process present in the invention. The bi-stable quantum wire array with quantum bit and kondo effect is prepared by self-assembling an oxygen radical antagonist of antioxidase, a ?-receptor agonist, a P2 receptor agonist, a calcium antagonist of phenyl alkyl amines, and/or a nucleotide monomer of purines and its binary, ternary, quaternary or quinary compounds and using the interaction of inelastic electron tunneling. The invention not only benefits mechanisms-targeted multifunctional device discoveries, but also profits inventions of nanometer structures, novel materials, quantum calculation devices, biosensors and quantum bit magnetic random access memories (MRAM).Type: ApplicationFiled: January 15, 2008Publication date: July 10, 2008Applicant: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Yan Fang, Rong Wu